VANCOUVER, Nov. 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. will host a live webcast of its vascular program update on Thursday, November 17th, 2005 beginning at 10:30 am EST (7:30 am PST) and concluding at approximately 12:00 pm EST (9:00 am PST).
Angiotech will be providing an update on its vascular initiatives including the Edwards Lifespan(R) Vascular Graft product line acquisition, the Vascular Wrap(TM) paclitaxel-eluting mesh program, vascular market opportunity and commercialization plans, and U.S. clinical trial and timelines update. The webcast will be available to all interested parties at Angiotech’s website at www.angiotech.com in the Investor Relations section. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes before the webcast begins.
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical company pioneering the combination of pharmaceutical compounds with medical devices and biomaterials to both create novel solutions for challenging disease states and improve surgical outcomes. To find out more about Angiotech Pharmaceuticals, Inc. , please visit our website at www.angiotech.com.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continue,” “estimate,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.
FOR ADDITIONAL INFORMATION: --------------------------- Analysts and Investors: Todd Young, Vice President Investor Relations and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Analysts: Rui Avelar, Senior Vice President Medical Affairs and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6996 Media: Colleen Beauregard, Waggener Edstrom Bioscience, (503) 443-7863, Email: colleenb@wagged.com
Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Investors: Todd Young, Vice President InvestorRelations and Communications, Angiotech Pharmaceuticals, Inc., (604)221-7676 ext 6933; Analysts: Rui Avelar, Senior Vice President MedicalAffairs and Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676ext 6996; Media: Colleen Beauregard, Waggener Edstrom Bioscience, (503)443-7863, Email: colleenb@wagged.com